What payer contract analytics is, in short
Payer contract analytics is the work of checking that every rebate a pharma manufacturer pays to a PBM or health plan was earned under the contract terms, and then measuring whether each contract delivered the access and volume it was signed for. It has two halves: validation, which catches rebates paid on ineligible claims, missed formulary terms or wrong prices before money leaves the company, and performance, which compares what the deal promised against what actually happened at plan and patient level.
For most mid-sized manufacturers, the validation half is where the money is. Rebate invoices arrive quarterly as large claim-level files, the contract terms sit in PDFs and spreadsheets, and the analysts who reconcile them have weeks, not months, before payment is due. Errors that nobody can find in that window are paid by default. The performance half matters at renewal, when the access team has to argue whether a deeper rebate bought anything.
This guide sets out the checks every rebate invoice should pass, the data each check needs, a worked example of what validation finds, how to choose between buying a platform and building on your own data, and when a spreadsheet is still enough. It is written for market access, trade, contracting and finance leaders at mid-sized and emerging pharma and biotech companies.
Why payer contract analytics matters more in 2026
The amounts at stake keep growing. Drug Channels Institute estimated in July 2026 that manufacturers' total gross-to-net reductions for brand-name drugs reached $416 billion in 2025, and noted that negotiated and statutory rebates paid to third-party payers remain the largest components of that gap.
Visibility has not kept up. Model N's 2026 State of Revenue Report, published on 10 February 2026 and based on a survey of more than 400 leaders at pharma and medtech companies with over $250 million in revenue, found that 99 percent say gross to net has become harder to manage, and 61 percent name PBMs as the leading contributor to that complexity. Fewer than 30 percent have fully integrated gross-to-net data across their pricing and reimbursement programmes, and only 1 percent have real-time visibility into Medicaid and Medicare rebates, 340B discounts and utilization rebates.
Smaller companies feel it most. In the same survey, 51 percent of companies above $5 billion in revenue felt fully prepared for government programme audits, against roughly one third of companies between $250 million and $5 billion. Model N estimates that pricing, rebate and compliance gaps cost US life sciences companies more than $50 billion a year in lost revenue. Treat that as a vendor's estimate, but the direction is clear: the companies with the least analytical capacity are paying the most rebates with the least checking.
Policy is adding work on top. Medicare negotiated prices, the 340B rebate pilot and state-level PBM reforms all change which claims are eligible for which rebate, and each change is another rule the validation logic has to apply. If those programmes touch your brands, our guides to the 340B rebate pilot for manufacturers and MFP effectuation cover the data side.
The checks every PBM rebate invoice should pass
Plan and book of business
Every claim should come from a plan that is inside the contracted book of business for that period. Plans move between PBMs and between commercial, Medicare and Medicaid lines, so the list has to be dated.
- Claims from plans outside the contract
- Plans that changed line of business
- Carve-outs named in the contract
Formulary position and access terms
Access rebates usually depend on a tier, parity with competitors, or limits on prior authorization and step therapy. MMIT describes contract validation as crosschecking those contracted terms against actual coverage data before rebates are paid.
- Tier placement by month
- Utilization management beyond label
- Competitor parity where required
Duplicates and reversals
The same claim can appear twice in one file, across two quarters, or after it was reversed at the pharmacy. Each one is a full rebate paid for nothing.
- Same claim key, same quarter
- Claims already paid last period
- Reversed claims still invoiced
Price basis and rates
The rebate is a percentage of a price at a point in time. A WAC change mid-quarter, a price protection clause or a tiered rate by market share all change the amount due.
- WAC on the claim date
- Correct tier of a tiered rate
- Price protection applied once
Product, NDC and quantity
Rebates apply to listed NDCs only. Package size mistakes, unit of measure errors and NDCs that were added or removed from the contract mid-term are frequent sources of overpayment.
- NDC in contract on claim date
- Units versus packages
- Days supply outliers
Overlap with other discounts
A unit should not attract a commercial rebate and a statutory discount that the contract excludes. 340B and Medicaid overlap is the best known case, and getting it wrong creates compliance exposure as well as cost.
- 340B identified claims
- Medicaid and commercial overlap
- Contract exclusions applied
The data behind rebate validation and contract performance
Each check above needs a specific dataset, and most of the effort in payer contract analytics goes into getting them to join.
- Contract terms. Rates, tiers, eligibility rules, price protection and exclusions, by plan and by period. In most mid-sized companies these sit in signed PDFs and a contracting team's spreadsheet. They have to be turned into a structured, dated rules table before anything can be automated.
- Rebate invoices and claim-level utilization files. The PBM's submission, usually quarterly, with one row per claim or per aggregated line. File layouts differ by PBM and change without notice, so every load needs checks for missing fields and shifted columns.
- Formulary and coverage history. Tier, prior authorization and step therapy status by plan and month, from a coverage data vendor or your own access team's tracking.
- A payer and plan hierarchy. The same plan appears under different names and IDs in the invoice, the formulary feed and claims data. A maintained payer hierarchy is what lets these join, and it is the step most often skipped.
- Price history. WAC by NDC and effective date from your pricing system, so every claim is valued at the right price.
- Independent volume data. Specialty pharmacy dispense data or licensed claims data, used to test whether invoiced volume is plausible and, for performance, to build a comparison group.
The performance half adds one more piece: the approved deal case. Tellius makes the point in its August 2026 guide that a contract should be measured against the model that justified it, with its assumptions about access and volume written down, and against a credible counterfactual rather than simple before and after. Our market access analytics guide works through a pull-through example on the same data, and our gross to net guide shows where validated rebates land in the waterfall and the accruals.
A worked example: what validation finds on one quarterly invoice
The figures below are illustrative, chosen to show the arithmetic, not taken from any client or survey.
The contract. A specialty brand has a commercial contract with one PBM: a 20 percent base rebate on WAC for every eligible claim, plus a 10 percent access rebate in any month the brand holds preferred tier with no prior authorization beyond the label. For simplicity, WAC is $1,000 per claim.
The invoice. The PBM invoices 10,000 claims for the quarter at the full 30 percent, or $300 per claim. The invoice totals $3,000,000.
| Finding | Claims | Overpayment per claim | Amount to dispute |
|---|---|---|---|
| Duplicate claims, already paid in the prior quarter | 300 | $300 (full rebate) | $90,000 |
| Claims from two plans that added a prior authorization for two months, so only the base rebate was due | 450 | $100 (the access rebate) | $45,000 |
| Claims from a plan that left the contracted book of business at the start of the quarter | 120 | $300 (full rebate) | $36,000 |
| Total | 870 | $171,000 |
In this example, 5.7 percent of the invoice is disputable. If the same pattern held across four quarters, that is $684,000 a year on a single contract. None of these errors needs advanced modelling to find. Each needs a dated plan list, a dated formulary history and a claim key that is stable across quarters, which is exactly what a team working from emailed spreadsheets usually does not have.
The same data then answers the performance question. If the brand held preferred status on most plans but volume on those plans grew no faster than on comparable plans without the access rebate, the extra 10 percent bought little, and the next negotiation should start from that evidence.
Payer contract analytics software, a services team, or your own build
Platform
Model N, IntegriChain, Vistex and IQVIA all sell contract, rebate and gross-to-net software, and MMIT sells contract validation against coverage data. A platform makes sense when you have many payer contracts, government programmes to calculate and a team ready to run a system. None of them publishes prices, so ask for a three-year quote with implementation.
Services
Several platform vendors and consultancies run rebate validation and adjudication as a managed service. This suits a company with a handful of contracts and no contracting operations team, but check how disputes are documented and whether you keep the rules and history if you leave.
Own build
If you already load specialty pharmacy, hub or claims data into a warehouse, contract rules, invoices and formulary history can sit beside them. Validation logic becomes transparent SQL your team can read, and the same tables feed pull-through and net price reporting.
Combine
Many manufacturers land here: the platform calculates and pays, and a copy of contract, invoice and payment data flows to the warehouse where it joins coverage, dispense and claims data for validation exceptions and performance reviews.
How we build payer contract analytics
Turn contracts into a rules table
We read the signed contracts and amendments with your contracting team and capture rates, tiers, eligibility, exclusions and price protection as dated rows that a query can apply.
Master plans, products and prices
We build or extend the payer hierarchy, the NDC list by contract period and the WAC history, so invoices, formulary data and claims join on stable keys.
Automate invoice loads
Each PBM's file gets its own pipeline with checks for missing fields, changed layouts and unexpected volume before anyone starts validating.
Run the validation checks
Duplicates, plan eligibility, formulary compliance, price basis, NDC and discount overlap run on every invoice, producing a claim-level exception list your analysts review rather than build.
Report performance by contract
Access achieved, volume against a comparison group and net price per claim, by contract and plan, ready for renewal discussions and the quarterly gross-to-net close.
Common mistakes in rebate validation
When you do not need payer contract analytics yet
A spreadsheet is still enough if you have one or two commercial contracts, a few hundred claims a quarter and an analyst who knows them well. Write the rules down, keep a dated plan list, and revisit when contracts multiply.
Do not build if your brand is pre-launch or not yet contracting with PBMs. Spend the effort on the access and patient services data that will feed these checks later, starting with the plan master. Our specialty pharmacy analytics hub covers that foundation.
Buy rather than build if you have dozens of contracts across commercial, Medicare and Medicaid lines, no data warehouse and no one to own a rules table. A platform or managed service will be faster, and you can add an analytics layer later.
Fix the data first if your rebate accruals and actual payments already disagree by more than finance can explain. Automated validation on a broken plan or product master just produces confident errors. Similar logic applies to trade-side deductions, covered in our guide to pharma chargeback management.
Where none of these apply, and you are paying material rebates with limited checking, Greenwolf builds the validation and performance layer on your own data, alongside whatever platform you already run. Our pharma commercial analytics consulting covers the wider work, and our founder came up through pharma commercial operations consulting at ZS, so we start from the reports your access and finance teams already use.
Questions about payer contract analytics
What is payer contract analytics in pharma?
What is contract validation in pharma?
What causes rebate leakage?
How often should rebate invoices be validated?
What data do you need for rebate validation?
Which software is used for payer contract analytics?
Can a mid-sized pharma company build this in-house?
Paying rebates you cannot fully check?
Tell us how many payer contracts you have, how invoices arrive and where the contract terms live today. We will map the validation and performance work in a short digital audit, including the data you already hold. Please do not send any patient information.
Part of our Pharma Commercial and Patient Analytics hub. Start with our specialty pharmacy analytics.